Trial Profile
An Extension Trial Comparing Safety and Efficacy of NN5401 With Insulin Glargine in Subjects With Type 2 Diabetes (BOOST: START 1) [EXTENSION OF 700052699]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec/insulin aspart (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms BOOST
- Sponsors Novo Nordisk
- 01 Dec 2015 Post-hoc pooled analysis results presented at the 23rd World Diabetes Congress of the International Diabetes Federation (IDF), as per Novo Nordisk media release.
- 16 Apr 2013 New trial record